Table 1.
General characteristics of the noncontrolled single-arm LMGB studies.
| Study characteristics | Baseline patient demographics | 1-year postoperative results | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author | Year | Region | Number (M/F) |
Age (range) |
BMI (kg/m2) |
Weight (kg) |
WC (cm) | T2DM patients |
%EWL | BMI (kg/m2)/ΔBMI | Weight/weight loss (kg) | Remission or improvement of T2DM |
| Carbajo et al. [18] | 2005 | Spain | 209 (37/172) |
41 (14–66) |
48 (39–86) |
NR | NR | NR | 75%, 80% at 18 months | NR/NR | NR/NR | NR |
|
| ||||||||||||
| Rutledge and Walsh [19] | 2005 | USA | 2410 (361/2049) |
39 (14–78) |
46 ± 7 (34–74) |
NR | NR | 24% | 80% | 29/NR | NR/59 | 83% |
|
| ||||||||||||
| Wang et al. [20] | 2005 | Taiwan | 423 (87/336) |
30.6 ± 9.3 (19–62) |
44.2 ± 7 (35.5–72.1) |
120.3 ± 23.4 (89–212.7) |
NR | 79 | 69.3% | 29.2/NR | NR | 100% |
|
| ||||||||||||
| Chakhtoura et al. [22] | 2008 | France | 100 (23/77) |
40.9 ± 11.5 (17.5–62.4) |
46.9 ± 7.4 (32.8–72.4) |
131 ± 23.1 (82–203) |
NR | None | 63 ± 14% | 31.9 ± 5.7/NR | 89.8 ± 18.4/NR | NR |
|
| ||||||||||||
| Lee et al. [23] | 2008 | Korea | 44 (6/38) 114 (33/81) 43 (19/24) |
39 ± 8.9 34.8 ± 9.2 28.2 ± 8.7 |
31.7 ± 2.7 40 ± 2.8 51.4 ± 6 |
143.1 ± 9.8 107.6 ± 5.1 81.2 ± 5.1 |
103.4 ± 7.1 117.6 ± 14.7 137.8 ± 15.3 |
All | NR | NR/8.5 ± 2.2 NR/12.4 ± 3.2 NR/17.9 ± 5.8 |
91.4 ± 9.8/NR 79.2 ± 5.5/NR 60.4 ± 3.3/NR |
87.1% |
|
| ||||||||||||
| Peraglie [25] | 2008 | USA | 16 (2/14) |
40 (27–61) |
62.4 (60–73) |
166 (150–193) |
NR | NR | 57%, 65% at 2 years | NR | NR/63 | NR |
|
| ||||||||||||
| Kim and Hur∗
[26] |
2011 | Korea | 10 (2/8) |
46.9 (29–59) |
27.2 (25.3–29.9) |
NR | NR | All | NR | NR/23.4 (21.3–25.6) |
NR/NR | 70% |
|
| ||||||||||||
| Piazza et al. [27] | 2011 | Italy | 197 (50/147) |
37.9 (20–55) |
52.9 | NR | NR | NR | 65%, 80% at 2 years | 39.4 ± 4.2/NR | NR/NR | 90% |
|
| ||||||||||||
| Noun et al. [28] | 2012 | Lebanon | 923 (315/606) |
32.77 ± 10 (13–70) |
42.5 ± 6.39 (35–75) |
121.64 ± 23.85 (80–240) |
NR | 19% | 69.9% ± 23.1% | 28.3 ± 4.8/NR | 80.3 ± 14.2/NR | 85% |
|
| ||||||||||||
| Kim and Hur [29] | 2014 | Korea | 107 (54/53) |
46 ± 11 (21–74) |
25.3 ± 3.2 (18–30) |
NR | NR | All | NR | 22.9 ± 3.0/NR | NR/NR | 53%, 63% at 2 and 90% at 3 years |
|
| ||||||||||||
| Kular et al. [31] | 2014 | India | 1054 (342/712) |
38.4 ± 9.6 | 43.2 ± 7.4 | 128.5 ± 25.2 | 118.2 ± 15.7 | 674 (64%) | 85%, 91% at 2 and 85% at 5 years | 26.2 ± 3.1/NR | NR | 93.2% of remission; 98% of improvement |
|
| ||||||||||||
| Musella et al. [32] | 2014 | Italy | 974 (475/499) |
39.4 | 48 ± 4.58 | NR | NR | 224 (22.9%) | 70.12 ± 8.35%, 77% at 5 years | 31.88 ± 4.91/NR | 91.5 ± 18.5/NR | 87%, 84.4% at 5 years |
NR: not reported; ∗postoperative results at 6 months.